Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study

OBJECTIVE: Binge eating disorder (BED) is the most common eating disorder, and yet only one pharmacotherapy (lisdexamfetamine), which has known abuse-potential, is FDA-approved. Topiramate is also commonly prescribed off-label for binge eating but has many contraindications. In contrast, the glucago...

Descripción completa

Detalles Bibliográficos
Autores principales: Richards, Jesse, Bang, Neha, Ratliff, Erin L., Paszkowiak, Maria A., Khorgami, Zhamak, Khalsa, Sahib S., Simmons, W. Kyle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661993/
https://www.ncbi.nlm.nih.gov/pubmed/37990682
http://dx.doi.org/10.1016/j.obpill.2023.100080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661993/
https://www.ncbi.nlm.nih.gov/pubmed/37990682
http://dx.doi.org/10.1016/j.obpill.2023.100080

Ejemplares similares